Eye-tracking Training for Older Adults
Eye Tracking as an Early Cognitive Intervention for Older Adults With Subjective Memory Complaints
The goal of this clinical trial is to learn if a computerized eye-tracking training program can improve mental health and thinking skills in older adults. The main questions it aims to answer are whether eye-tracking training can lower depressive and anxiety symptoms in older adults, and whether it can improve their ability to control impulses and pay attention.
Researchers will compare older adults who receive eye-tracking training to older adults on a waitlist to see if eye-tracking training leads to greater improvements in mood and thinking skills.
Researchers will randomly assign participants into the experimental group or the waitlist control group. Participants in the experimental group will take part in eye-tracking training three times a week for 18 sessions, over about 1.5 months. Before and after training, participants will answer questions about their mood and take tests of memory, attention, and impulse control. Older adults on the waitlist will complete the same tests but will not receive training until after the study period; they will be offered the same training once their waiting period ends.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Hong Kong, Hong Kong, 0000
- Research Center for Neuropsychological Well-being
-
Hong Kong, Hong Kong
- International Women's League Neighbourhood Elderly Centre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Community-dwelling Chinese older adults aged 60 to 80 years
- Able to understand Cantonese/Chinese
- Normal or corrected-to-normal vision
- Willing and able to commit to attending 18 training sessions over the course of the intervention
Exclusion Criteria:
- A history of learning disability, psychiatric disorders, neurological disorders (e.g., head injury or Parkinson's disease), visual and/or hearing impairments, or any other physical disabilities that would affect their performance on neuropsychological assessment or adherence to the intervention
- Prior or concurrent participation in other interventions involving eye-tracking techniques
- Signs of dementia, as indicated by a total score of 18 or below on the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA)
- Inability to commit to the full course of 18 training sessions
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Eye-Tracking Training
Participants receive computerized eye-tracking training for 18 one-hour sessions, three times weekly, over approximately 6 weeks.
|
The intervention is a copyrighted computerized training program using a non-contact eye tracker.
Participants are required to fixate on or trace visual targets across six modules of increasing difficulty to improve attention and inhibitory control.
|
|
Aucune intervention: Waitlist control
Participants in this group do not receive eye-tracking training during the study period and complete the same baseline and post-assessment schedule as the experimental group.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Inhibitory control
Délai: Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
Inhibitory Control Index (ICI) in the Eriksen Flanker Test
|
Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
|
Sustained attention
Délai: Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
Digit Cancellation Index (DCI) in the Digit Cancellation Test
|
Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
|
Depressive symptoms
Délai: Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
Depressive symptoms are assessed using the 15-item Chinese version of Geriatric Depressive Scale (CGDS-15).
It is a 15-item self-report scale in which participants answer "Yes" or "No" to whether they experienced each of 15 common depressive symptoms in the past week.
Scores range from 0 to 15, with higher scores indicating more depressive symptoms.
A score of 8 or higher indicates clinically significant depressive symptoms.
|
Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
|
Anxiety symptoms
Délai: Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
Anxiety symptoms are assessed using the 10-item Chinese version of Geriatric Anxiety Scale (CGAS-10).
It is a 10-item self-report measure of anxiety symptoms in older adults.
Higher scores indicate greater severity of anxiety symptoms.
|
Baseline and after completion of 18 training sessions (approximately 9 weeks)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2022.625
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .